Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase

Gary B. Evans, Richard H. Furneaux, Vern L. Schramm, Vipender Singh, Peter C. Tyler

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The polyamine biosynthetic pathway is a therapeutic target for proliferative diseases because cellular proliferation requires elevated levels of polyamines. A byproduct of the latter stages of polyamine biosynthesis (the synthesis of spermidine and spermine) is 5′-methylthioadenosine (MTA). In humans, MTA is processed by 5′-methylthioadenosine phosphorylase (MTAP) so that significant amounts of MTA do not accumulate. Potent inhibitors of MTAP might allow the buildup of sufficient levels of MTA to generate feedback inhibition of polyamine biosynthesis. We have designed and synthesized a family of potential transition-state analogue inhibitors of MTAP on the basis of our knowledge of the transition-state structure of purine nucleoside phosphorylase and the assumption that it is likely the two enzymes share a common catalytic mechanism. Several of the inhibitors display slow-onset tight-binding properties, consistent with them being transition-state analogues, with the most potent having a dissociation constant of 166 pM.

Original languageEnglish (US)
Pages (from-to)3275-3281
Number of pages7
JournalJournal of Medicinal Chemistry
Volume47
Issue number12
DOIs
StatePublished - Jun 3 2004

Fingerprint

Polyamines
Biosynthesis
Purine-Nucleoside Phosphorylase
Spermidine
Spermine
Biosynthetic Pathways
Byproducts
Cell Proliferation
Feedback
5'-methylthioadenosine phosphorylase
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase. / Evans, Gary B.; Furneaux, Richard H.; Schramm, Vern L.; Singh, Vipender; Tyler, Peter C.

In: Journal of Medicinal Chemistry, Vol. 47, No. 12, 03.06.2004, p. 3275-3281.

Research output: Contribution to journalArticle

Evans, Gary B. ; Furneaux, Richard H. ; Schramm, Vern L. ; Singh, Vipender ; Tyler, Peter C. / Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase. In: Journal of Medicinal Chemistry. 2004 ; Vol. 47, No. 12. pp. 3275-3281.
@article{146998a2e84848b280b3e2a64e9cc773,
title = "Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase",
abstract = "The polyamine biosynthetic pathway is a therapeutic target for proliferative diseases because cellular proliferation requires elevated levels of polyamines. A byproduct of the latter stages of polyamine biosynthesis (the synthesis of spermidine and spermine) is 5′-methylthioadenosine (MTA). In humans, MTA is processed by 5′-methylthioadenosine phosphorylase (MTAP) so that significant amounts of MTA do not accumulate. Potent inhibitors of MTAP might allow the buildup of sufficient levels of MTA to generate feedback inhibition of polyamine biosynthesis. We have designed and synthesized a family of potential transition-state analogue inhibitors of MTAP on the basis of our knowledge of the transition-state structure of purine nucleoside phosphorylase and the assumption that it is likely the two enzymes share a common catalytic mechanism. Several of the inhibitors display slow-onset tight-binding properties, consistent with them being transition-state analogues, with the most potent having a dissociation constant of 166 pM.",
author = "Evans, {Gary B.} and Furneaux, {Richard H.} and Schramm, {Vern L.} and Vipender Singh and Tyler, {Peter C.}",
year = "2004",
month = "6",
day = "3",
doi = "10.1021/jm0306475",
language = "English (US)",
volume = "47",
pages = "3275--3281",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase

AU - Evans, Gary B.

AU - Furneaux, Richard H.

AU - Schramm, Vern L.

AU - Singh, Vipender

AU - Tyler, Peter C.

PY - 2004/6/3

Y1 - 2004/6/3

N2 - The polyamine biosynthetic pathway is a therapeutic target for proliferative diseases because cellular proliferation requires elevated levels of polyamines. A byproduct of the latter stages of polyamine biosynthesis (the synthesis of spermidine and spermine) is 5′-methylthioadenosine (MTA). In humans, MTA is processed by 5′-methylthioadenosine phosphorylase (MTAP) so that significant amounts of MTA do not accumulate. Potent inhibitors of MTAP might allow the buildup of sufficient levels of MTA to generate feedback inhibition of polyamine biosynthesis. We have designed and synthesized a family of potential transition-state analogue inhibitors of MTAP on the basis of our knowledge of the transition-state structure of purine nucleoside phosphorylase and the assumption that it is likely the two enzymes share a common catalytic mechanism. Several of the inhibitors display slow-onset tight-binding properties, consistent with them being transition-state analogues, with the most potent having a dissociation constant of 166 pM.

AB - The polyamine biosynthetic pathway is a therapeutic target for proliferative diseases because cellular proliferation requires elevated levels of polyamines. A byproduct of the latter stages of polyamine biosynthesis (the synthesis of spermidine and spermine) is 5′-methylthioadenosine (MTA). In humans, MTA is processed by 5′-methylthioadenosine phosphorylase (MTAP) so that significant amounts of MTA do not accumulate. Potent inhibitors of MTAP might allow the buildup of sufficient levels of MTA to generate feedback inhibition of polyamine biosynthesis. We have designed and synthesized a family of potential transition-state analogue inhibitors of MTAP on the basis of our knowledge of the transition-state structure of purine nucleoside phosphorylase and the assumption that it is likely the two enzymes share a common catalytic mechanism. Several of the inhibitors display slow-onset tight-binding properties, consistent with them being transition-state analogues, with the most potent having a dissociation constant of 166 pM.

UR - http://www.scopus.com/inward/record.url?scp=2542531592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542531592&partnerID=8YFLogxK

U2 - 10.1021/jm0306475

DO - 10.1021/jm0306475

M3 - Article

C2 - 15163207

AN - SCOPUS:2542531592

VL - 47

SP - 3275

EP - 3281

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 12

ER -